Navigation Links
ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
Date:2/23/2009

LEUVEN, Belgium and LUND, Sweden, February 23 /PRNewswire-FirstCall/ --

- Trial to Assess the Benefits of Partial Factor VIII Inhibition in Patients Undergoing Knee Replacement Surgery

ThromboGenics NV (Euronext Brussels: THR) and co-development partner BioInvent International (OMXS: BINV) announce today that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the prophylaxis of Deep Vein Thrombosis (DVT) following orthopaedic surgery. TB-402, which is given as a single injection post surgery, could overcome the major drawbacks such as bleeding and the need for extensive patient monitoring associated with current anti-coagulant therapy.

TB-402 is a recombinant human monoclonal antibody that targets Factor VIII, a key component of the coagulation cascade. TB-402 is a novel anticoagulant agent, which may deliver important clinical benefits due to it only partially inhibiting Factor VIII activity even when given in very high doses. This novel mode of action is expected to reduce the risk of undesirable bleeding events and the need for patient monitoring, the two main drawbacks associated with current anticoagulants. In addition, TB-402 is a long-acting agent which means that patients are expected to receive just one single dose after surgery to prevent the development of DVT, as opposed to all current treatment options which require daily treatment for up to several weeks.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomised, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. The study will assess three different doses of TB-402 given as a single intravenous bolus injection post knee replacement surgery. The trial will enrol 300 patients across 36 centers mainly in Central Europe. The primary endpoint is the safety and efficacy of the three
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics N.V.: Business Update
2. ThromboGenics Announces Half Year Results 2008
3. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
4. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
5. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
6. ThromboGenics N.V. - Business Update
7. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
10. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
11. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)... Nov. 25 Reportlinker.com announce...n its catalogue: ,, Brazil Bioethanol Market A...eportlinker.com/p0165503/Brazil-Bioethanol-Market-...Bioethanol Market Analysis and Forecasts to 2013 ,...analysis and forecasts of the global bioethanol ma...
(Date:11/24/2009)...he New York investment bank KTA Capital,s client N...AU$6.7 mil convertible note private placement with...ent was arranged by KTA Capital as Neuren,s exclus... New York (PRWEB) November 23, 2009 -- Th..., LLC ("KTA Capital") has announced that...
(Date:11/24/2009)...Health care employment grew by 29,000 jobs in Oct...onsistent growth during the U.S. recession. Howeve...le, and health systems are coming closer to having...t administrators. , (Vocu...tinued growing in October despite the shedding of ...
(Date:11/24/2009)...4 Blue Marble Energy Corp. announc...velopment Authority (OPDA) were recently awarded $... Revitalization Board (CERB) in a private/public p...y biochemical biorefinery in Lincoln County, WA. ...he development of our biorefinery and bring over 7...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 10KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...Germany, August 1 , - Further Focus on Pharma & L...s business in technical plastic,systems. The busin...omponents for suppliers to the automobile industry...e science. For this purpose the sale process,has b...r bids., "Through the sale of the technical plast...
...if., July 31 Thermage, Inc.,(Nasdaq: THRM ), ann...sults,for the second quarter ended June 30, 2008, ... The Company will also host a conference call and,...Eastern Time (5:30 a.m.,Pacific) to discuss the fi.... The dial-in number for the conference call is 80...
...enue Grows 15 Percent Quarter-over-Quarter -, PAL...daq: CVTX ) today reported financial results for ...quarter ended June 30, 2008, the Company reported ...is compares to a net loss of $31.9,million, or $0...., 2008 and,$57.6 million, or $0.97 per share, for ...
Other Biology Technology:Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics 2CV Therapeutics Reports 2008 Second Quarter Financial Results 2CV Therapeutics Reports 2008 Second Quarter Financial Results 3CV Therapeutics Reports 2008 Second Quarter Financial Results 4CV Therapeutics Reports 2008 Second Quarter Financial Results 5CV Therapeutics Reports 2008 Second Quarter Financial Results 6CV Therapeutics Reports 2008 Second Quarter Financial Results 7
(Date:11/26/2009)...rks are some of the Ocean,s most distinctive resid...this strange head shape, says Michelle McComb fro... is the shark,s vision. ,Perhaps their visual fiel...ys McComb, giving the sharks excellent stereovisio...mb, there were two schools of thought on this theo...
(Date:11/26/2009)...ir impressive antlers, red deer have been caught i...s antlers are much more than decorative. They are ...ling. John Currey, from The University of York, UK...of bone for over half a century and has become fas...ough a long-standing collaboration with Tomas Land...
(Date:11/26/2009)...e at last worked out a way of using recordings of ...pulations. This is the first time sound recordings... accurate estimates of bird species, populations. ... Ecological Society,s Journal of Applied Ecology ... a major advance in our ability to monitor whale a...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2Tough yet stiff deer antler is materials scientist's dream 2Ecologists sound out new solution for monitoring cryptic species 2Water quality in orbit 9906 1Water quality in orbit 9906 2Water quality in orbit 9906 3Water quality in orbit 9906 4Looking deeply into polymer solar cells 14009 1Looking deeply into polymer solar cells 14009 2Drug Offers Hope Against Tough to Treat Hypertension 56993 1Drug Offers Hope Against Tough to Treat Hypertension 56993 2Drug Offers Hope Against Tough to Treat Hypertension 56993 3
...s E. coli bacterium, which has one-seventh the num...em involved in metabolism and metabolic regulation... would theoretically be capable of generating a hu...s at UCSD will report in the Dec. 27 issue of Proc... that Escherichia coli doesn,t gamble with its met...
...ult for a terrorist to obtain genes from the small...it,s not. Armed with a fake email address, a would... blocks of a deadly biological weapon online, and ...bering reality uncovered by a New Scientist invest...ing business of gene synthesis. Dozens of biotech ...
...consumers in Asia have received a little good news...rading nations remain deadlocked on how to move ah...he poor farmers of the developing world, research ...trategy to reduce poverty in the planet,s two most...rch shows that, in 1999, for every US$1 million in...
Other Biology News:How E. coli bacterium generates simplicity from complexity 2How E. coli bacterium generates simplicity from complexity 3The bioweapon is in the post 2The bioweapon is in the post 3The bioweapon is in the post 4Some good news for the world's poor 2Some good news for the world's poor 3Some good news for the world's poor 4
... using Asuragens bioinformatics expertise. We offe...ive data analysis using the most up to date method...ene Expression Profiling Service or from your own ...sic statistical analysis including publication qua...
CORNING ROLLER BOTTLE WITH CELLBIND, 1700CM2, STERILE from Sigma-Aldrich
...ne produced by activated T cells, monocytes, and K...ome tumour and normal cell lines, simulates fibrob...feration, cytokine release from endothelial cells ... hepatoma cells. Mouse OSM was recently cloned and...
...arvard Apparatuss best pump mechanism, a well thou...ration options. A lookup table in the pumps softwa...e major manufacturers. A bright, two line display ...cross the lab. All models have RS-232 and TTL port...
Biology Products: